Zydus Cadila gets USFDA’s nod for Bosentan Tablets, Trientine Hydrochloride Capsules

30 Apr 2019 Evaluate

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Bosentan Tablets USP (US RLD-Tracleer Tablets), 62.5 mg and 125 mg and Trientine Hydrochloride Capsules USP (US RLD-Syprine Capsules), 250 mg.

Both the products will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Bosentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). Trientine is used to treat this inherited condition in people who cannot take penicillamine.

The group now has 265 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

890.60 14.25 (1.63%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×